Sphingosine kinase 2 inhibition and blood sphingosine 1-phosphate levels

Journal of Pharmacology and Experimental Therapeutics

Volumn 355, Issue 1, 2015, Pages 23-31

  Kharel, Yugesh ^a   Morris, Emily A ^b   Congdon, Molly D ^b   Thorpe, Steven B ^c   Tomsig, Jose L ^a   Santos, Webster L ^b   Lynch, Kevin R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c SphynKx Therapeutics LLC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; ISOENZYME; SLC 5111312; SLM 6031434; SLM 6081442; SLR 080811; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 2; UNCLASSIFIED DRUG; LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; GENE FUNCTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RAT; STRUCTURE ANALYSIS; TISSUE LEVEL; U937 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG DESIGN; ENZYME SPECIFICITY;

ANIMALS; DRUG DESIGN; ENZYME INHIBITORS; LYSOPHOSPHOLIPIDS; MALE; MICE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RATS; SPHINGOSINE; SUBSTRATE SPECIFICITY;

EID: 84941633960     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.225862     Document Type: Article

References (22)

1. Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, Van Echten-Deckert G, Hajdu R, Rosenbach M, Keohane CA, and Mandala S, et al. (2004) Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 279:52487-52492.
2. Allende ML, Sipe LM, Tuymetova G, Wilson-Henjum KL, Chen W, and Proia RL (2013) Sphingosine-1-phosphate phosphatase 1 regulates keratinocyte differentiation and epidermal homeostasis. J Biol Chem 288:18381-18391.
3. Bektas M, Allende ML, Lee BG, Chen W, Amar MJ, Remaley AT, Saba JD, and Proia RL (2010) Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver. J Biol Chem 285:10880-10889.
4. Kennedy AJ, Mathews TP, Kharel Y, Field SD, Moyer ML, East JE, Houck JD, Lynch KR, and Macdonald TL (2011) Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem 54:3524-3548.
5. Kharel Y, Mathews TP, Gellett AM, Tomsig JL, Kennedy PC, Moyer ML, Macdonald TL, and Lynch KR (2011) Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate. Biochem J 440:345-353.
6. Kharel Y, Raje M, Gao M, Gellett AM, Tomsig JL, Lynch KR, and Santos WL (2012) Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. Biochem J 447:149-157.
7. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, and Proia RL (2005) Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 25:11113-11121.
8. Patwardhan NN, Morris EA, Kharel Y, Raje MR, Gao M, Tomsig JL, Lynch KR, and Santos WL (2015) Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. J Med Chem 58:1879-1899.
9. Peest U, Sensken SC, Andréani P, Hänel P, Van Veldhoven PP, and Gräler MH (2008) S1P-lyase independent clearance of extracellular sphingosine 1-phosphate after dephosphorylation and cellular uptake. J Cell Biochem 104:756-772.
10. Pitson SM, Moretti PA, Zebol JR, Lynn HE, Xia P, Vadas MA, and Wattenberg BW (2003) Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 22:5491-5500.
11. Rex K, Jeffries S, Brown ML, Carlson T, Coxon A, Fajardo F, Frank B, Gustin D, Kamb A, and Kassner PD, et al. (2013) Sphingosine kinase activity is not required for tumor cell viability. PLoS One 8:e68328.
12. Rosen H, Sanna MG, Cahalan SM, and Gonzalez-Cabrera PJ (2007) Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol 28:102-107.
13. Salous AK, Panchatcharam M, Sunkara M, Mueller P, Dong A, Wang Y, Graf GA, Smyth SS, and Morris AJ (2013) Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice. J Lipid Res 54:2775-2784.
14. Schnute ME, McReynolds MD, Kasten T, Yates M, Jerome G, Rains JW, Hall T, Chrencik J, Kraus M, and Cronin CN, et al. (2012) Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J 444:79-88.
15. Schwab SR and Cyster JG (2007) Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 8:1295-1301.
16. Sensken SC, Bode C, Nagarajan M, Peest U, Pabst O, and Gräler MH (2010) Redistribution of sphingosine 1-phosphate by sphingosine kinase 2 contributes to lymphopenia. J Immunol 184:4133-4142.
17. Shaner RL, Allegood JC, Park H, Wang E, Kelly S, Haynes CA, Sullards MC, and Merrill AH, Jr (2009) Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers. J Lipid Res 50:1692-1707.
18. Takuwa N, Ohkura S, Takashima S, Ohtani K, Okamoto Y, Tanaka T, Hirano K, Usui S, Wang F, and Du W, et al. (2010) S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res 85:484-493.
19. Tomsig JL, Snyder AH, Berdyshev EV, Skobeleva A, Mataya C, Natarajan V, Brindley DN, and Lynch KR (2009) Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem J 419:611-618.
20. Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, Parikh NS, Habrukowich C, and Hla T (2008) Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res 102:669-676.
21. Zemann B, Kinzel B, Müller M, Reuschel R, Mechtcheriakova D, Urtz N, Bornancin F, Baumruker T, and Billich A (2006) Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107:1454-1458.
22. Zhang Y, Berka V, Song A, Sun K, Wang W, Zhang W, Ning C, Li C, Zhang Q, and Bogdanov M, et al. (2014) Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. J Clin Invest 124:2750-2761.